D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?

Nasal polyposis (NP) is a an uncomfortable condition in chronic sinusitis with relapsing inflammation despite of sinus surgery, intake of steroids and aspirin desensitization. Monoclonal antibodies (MAB) offer a new and prosperous treatment option in NP. Up to now there are no data of a combined aspirin and MAB regimen.

We examined 61 patients not responding adequately to aspirin desensitization then on dupilumab therapy. One group stuck on aspirin as add-on, the other received dupilumab solely. Quality of lifeparameters, rhinoscopy and NO levels were surveyed.

SNOT-scores, polyp and nasal inflammmation scores, FeNO and nasal NO levels improved significantly, but showed no difference before and after treatment of at least one year between both groups.

Dupilumab causes a significant improvement in the majority of chronic sinusitis patients with NP. Additional aspirin reveals no change in outcome under therapy. As it may be seen as a causal therapy, the further course without dupilumab should be observed.